Valid treatment options for osteoporosis and osteopenia in HIV-infected persons

Annals of Pharmacotherapy

Volumn 42, Issue 5, 2008, Pages 670-679

  Clay, Patrick G ^a,b,c   Voss, Laura E ^b   Williams, Charlott ^a   Daume, Eric C ^b  

^a KANSAS CITY UNIVERSITY OF MEDICINE AND BIOSCIENCES   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c Dybedal Center for Clinical Research   (United States)

Author keywords

Antiretrovirats; Bisphosphonates; HIV AIDS; Osteopenia; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; DARUNAVIR; DELAVIRDINE; EFAVIRENZ; ESTROGEN; ETRAVIRINE; IBANDRONIC ACID; INDINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; RITONAVIR; STEROID; STRONTIUM RANELATE; TESTOSTERONE; UNINDEXED DRUG; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE DISEASE; CALCIUM INTAKE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CREATININE CLEARANCE; DIET SUPPLEMENTATION; DOSE CALCULATION; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; EMBASE; ESOPHAGUS DISEASE; HORMONAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION RETRIEVAL; KIDNEY FAILURE; KINESIOTHERAPY; MEDICAL LITERATURE; MEDLINE; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SCREENING; TREATMENT DURATION; UNITED STATES; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE;

BONE DISEASES, METABOLIC; HIV INFECTIONS; HUMANS; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 42949121932     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K465     Document Type: Review

References (69)

1. Armosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis 2006;42:108-14. DOI 10.1086/498511
2. Annapoorna N, Venkateswara G, Reddy N, et al. An increased risk of osteoporosis during acquired immunodeficiency syndrome. Int J Med Sci 2004;1:152-64.
3. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95.
4. Brown T, Qaqish R. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006;20:2165-74.
5. Qaqish R, Sims K. Bone disorders associated with the human immunodeficiency virus: pathogenesis and management. Pharmacotherapy 2004;24:1331-46. DOI 10.1592/phco.24.14.1331.43150
6. Bruera D, Luna N, David D, et al. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003;17:1917-23.
7. Teichmann J, Stephan E, Lange U, et al. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect 2003;46:221-7. DOI 10.1053/jinf.2002.1109
8. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002;31:257-75.
9. National Osteoporosis Foundation. 2003. Treatment guidelines. www.nof.org/physguide/impact_and_overview.htm#synopsis (accessed 2007 Jul 8).
10. Fairfield WP, Finkelstein JS, Klibanski A, Grinspoon SK. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. J Clin Endocrinol Metab 2001;86:2020-6.
11. Arnsten JH, Freeman R, Howard AA, et al. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007;21:617-23.
12. Agents that affect bone mineral homeostasis. Antiviral agents. In: Katsung B. Basic & clinical pharmacology. 10th ed. New York: The McGraw-Hill Companies, 2001:716-32, 801-27.
13. Bartlett JG, Lane CL, eds. US DHHS guidelines for the use of antiretroviral agents in HIV-1 adults and adolescents. December 1, 2007 (accessed via: http://aidsinfo.nih.gov) (accessed 2008 Jan 4).
14. Clay PG, Lam AI. Testosterone replacement therapy for bone loss prevention in HIV-infected males. Ann Pharmacother 2003;37:582-5. DOI 10.1345/aph.1C345
15. Eichner SF, Lloyd KB, Timpe EM. Comparing therapies for post-menopausal osteoporosis prevention and treatment. Ann Pharmacother 2003;37:711-24. DOI 10.1345/aph.1C246
16. Package insert. Evista (raloxifene). Indianapolis: Eli Lilly and Company, September 2007.
17. Sambrook PN, Guesens P, Ribot C, et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in post-menopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med 2004;255:503-11. DOI 10.1111/j.1365-2796.2004.01317.x
18. Package insert. Miacalcin (calcitonin salmon) nasal spray. East Hanover, NJ: Novartis, June 2006. www.drugs.com/MMX/Alfacalcidol.html (accessed 2008 Jan 8).
19. Dursun N, Dursun E, Yalcin S. Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. Int J Clin Pract 2001;55:505-9.
20. Package insert. Forteo (teriparatide). Indianapolis: Eli Lilly and Company, April 2007.
21. Crans G, Silverman S, Genant H, et al. Association of severe vertebral fractures with reduced quality of life. Arthritis Rheum 2004;50:4028-34. DOI 10.1002/art.20671
22. Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metabol 2002;87:4528-35. DOI 10.1210/jc.2002-020334
23. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39.
24. Canalis E, Giustina A, Bilezikian JP. Mechanism of anabolic therapies for osteoporosis. N Engl J Med 2007;357:905-16.
25. Finkelstein JS, Leder BZ, Burnett SM, et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metabol 2006;91:2882-7. DOI 10.1210/jc.2006-0190
26. Iwamoto J, Takeda T, Sato Y, et al. Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis. Yonsei Med J 2005;46:750-8.
27. Package insert. Actonel (risedronate) Cincinnati, OH: Aventis Pharmaceuticals Inc., May 2007.
28. Package insert. Boniva (ibandronate sodium) tablets. Nutley, NJ: Roche Laboratories Inc., August 2006.
29. Package insert. Fosamax (alendronate sodium) tablets. Whitehouse Station, NJ: Merck & Co., Inc., April 2004.
30. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-11. DOI 10.1002/1529-0131(200101)44:1〈202:: AID-ANR27〉3.0.CO;2-W
31. Kushida K, Shiraki M, Nakamura T, et al. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study. J Bone Miner Metab 2004;22:462-8. DOI 10.1007/s00774-004-0508-0
32. Lanza F, Schwartz H, Sahba B, et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 2000;95:3112-7. DOI 10.1111/j.1572-0241.2000.03258.x
33. Guaraldi G, Orlando G, Madeddu G, et al. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials 2004;5:269-77.
34. Mondy K, Powderly W, Claxton S, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infections. J Acquir Immune Defic Syndr 2005;28:426-31.
35. McComsey GA, Kendall M, Tebas P, et al. Alendronate with calcium and vitamin D supplementation is superior to calcium and vitamin D alone in the management of decreased bone mineral density in HIV. AIDS 2007;30:2473-82.
36. Negredo E, Martinez-Lopez E, Paredes R, et al. Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. AIDS 2005;19:341-50.
37. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604-10.
38. Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 2001;86:5252-5.
39. Cooper A, Drake J, Brankin E, et al. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006;60:896-905. Epub 9 Jun 2006. DOI 10.1111/j.1742-1241.2006.01059.x
40. Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895-203. DOI 10.1185/030079905X74862
41. Greenspan SL, Nelson JB, Trump DL, et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007;20:416-24.
42. Cortet B, Bera-Louville A, Gauthier P, et al. Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. Effect of adding hormone replacement therapy. Joint Bone Spine 2001;68:410-5. DOI 10.1016/S1297-319X(01)00297-4
43. Hosking D, Adami S, Felsenberg D, et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin 2003;19:383-94. DOI 10.1185/030079903125002009
44. Seba AI, Bonnick SL, Kagan R, et al. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr Med Res Opin 2004;20:2031-41. DOI 10.1185/030079904X16768
45. Bonnick S, Saag KG, Kiel DP, et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 2006;91:2631-7. Epub 2006 Aug 24. DOI 10.1210/jc.2005-2602
46. Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005;20:141-51. Epub 2004 Sep 9. DOI 10.1359/JBMR.040920
47. Walgreens. www.walgreens.com/library/finddrug/druginfosearch.jsp (accessed 2007 Jul 16).
48. Halkin H, Dushenat M, Silverman B, et al. Brand versus generic alendronate: gastrointestinal effects measured by resource utilization. Ann Pharmacother 2007;41:29-34. Epub 26 Dec 2006. DOI 10.1345/aph.1H218
49. Package insert. Zometa (zoledronic acid). East Hanover, NJ: Novartis Pharmaceuticals Corporation, September 2007.
50. Saag K, Lindsay R, Kriegman A, et al. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 2007;40:1238-43. Epub 2007 Feb 8. DOI 10.1016/j.bone.2007.01.016
51. Ringe JD, Dorst A, Faber H, et al. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 2004;24:110-3. DOI 10.1007/s00296-003-0388-y
52. Jacobs JW, de Nijs RN, Lems WF, et al. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis. J Rheumatol 2007;34:1051-7. Epub 2007 Apr 1.
53. de Nijs RN, Jacobs JW, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006;355:675-84.
54. Ones K, Schacht E, Dukas L, et al. Effects of combined treatment with alendronate and alfacalcidol on bone mineral density and bone turnover in postmenopausal osteoporosis: a two-year, randomized, multiarm, controlled trial. Internet J Epidemiol 2007;4. www.ispub.com/ostia/index. php?xmlFilePath= journals/ije/vol4n1/bone.xml (accessed 2008 Jan 8).
55. Ringe JD, Farahmand P, Schacht E, et al. Superiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin D or alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int 2007;27:425-34.
56. Rhee Y, Kang M, Min Y, et al. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean post-menopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Osteoporos Int 2006;17:1801-7. Epub 2006 Sep 26. DOI 10.1007/s00198-006-0200-4
57. Reginster JY, Deroisy R, Jupsin I. Strontium ranelate: a new paradigm in the treatment of osteoporosis. Drugs Today 2003;39:89-101. DOI 10.1358/dot.2003.39.2.799416
58. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68.
59. Bruyere O, Roux C, Detilloux J, et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 2007;92:3076-81. Epub 2007 Jun 12. DOI 10.1210/jc.2006-2758
60. Blake GM, Fogelman I. The correction of BMD measurements for bone strontium content. J Clin Densitom 2007;10:259-65. Epub 2007 Jun 1. DOI 10.1016/j.jocd.2007.03.102
61. Bonnick S, Broy S, Kaiser F, et al. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. Curr Med Res Opin 2007;23:1341-9. DOI 10.1185/030079907X188035.
62. National Osteoporosis Foundation. 1999. Osteoporosis report. www.nof.org/prevention/calcium_supplements (accessed 2007 8 Jul).
63. Seattle Treatment Education Project. Calcium may offer hope to diarrhea sufferers. 2000. The Body. www.thebody.com/content/treat/art2006.html (accessed 18 Jul 2007).
64. Madeddu G, Spanu A, Solinas P, et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 2004;48:39-48.
65. Kiralti BJ, Srinivas S, Perkash I, et al. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001;57:127-32. DOI 10.1016/S0090-4295(00)00895-5
66. Dolan SE, Carpenter S, Grinspoon SK. Effects of weight, body composition, and testosterone on bone mineral density in HIV-infected women. J Acquir Immune Defic Syndr 2007;45:161-7.
67. Package insert. Androgel (testosterone transdermal system). Marietta, GA: Unimed Pharmaceuticals, April 2007.
68. Bruder JM, Ma JZ, Wing N, et al. Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy. J Clin Densitom 2006;9:431-7. Epub 2006 Sep 6.
69. Shimon I, Eshed V, Doolman R, et al. Alendronate for osteoporosis in men with androgen-repleted hypogonadism. Osteoporosis Int 2005;16: 1591-6. Epub 2005 Mar 15. DOI 10.1007/s00198-005-1879-3